UC Santa Cruz researchers highlight overlooked peptide P3 as potential Alzheimer's contributor

Scientists at the University of California, Santa Cruz have published work drawing attention to P3, a peptide derived from the same amyloid precursor protein (APP) that produces amyloid beta, but generated by a different enzymatic cleavage pathway. Where amyloid beta has dominated Alzheimer's research and drug development for decades, P3 has generally been regarded as an inert by-product.

The UCSC team report that P3 can form protein aggregates — structures analogous to the plaques associated with amyloid beta — and does so at a faster rate than amyloid beta under experimental conditions. The researchers also present evidence that P3 aggregates can damage cultured brain cells, suggesting a potential cytotoxic mechanism that has largely been overlooked in the field.

The work does not propose P3 as a replacement explanation for Alzheimer's pathology but rather suggests it may act alongside amyloid beta and tau — the two proteins that have defined the dominant disease models. If replicated, the finding could broaden the mechanistic picture of Alzheimer's and inform future research directions.

The full peer-reviewed publication details were not specified in feed reporting. The broader context is one of ongoing re-evaluation within Alzheimer's research: numerous amyloid-targeted therapies have produced disappointing results in trials, prompting interest in alternative or complementary disease mechanisms. This summary is based on public reporting of the research and does not constitute a clinical recommendation.